AMOXICILLIN PEDIATRIC Drug Patent Profile

Which patents cover Amoxicillin Pediatric, and what generic alternatives are available?

Amoxicillin Pediatric is a drug marketed by Teva and is included in one NDA.

The generic ingredient in AMOXICILLIN PEDIATRIC is amoxicillin. There are forty-six drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the amoxicillin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amoxicillin Pediatric

A generic version of AMOXICILLIN PEDIATRIC was approved as amoxicillin by TEVA on December 22^nd, 1992.

Summary for AMOXICILLIN PEDIATRIC

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AMOXICILLIN PEDIATRIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	AMOXICILLIN PEDIATRIC	amoxicillin	FOR SUSPENSION;ORAL	061931-003	Dec 1, 1982	AB	RX	No	No

Amoxicillin Pediatric Market: Investment Fundamentals Analysis

Last updated: February 19, 2026

Amoxicillin pediatric formulations represent a mature but consistently demanded segment of the antibiotic market. Key investment considerations include stable prescription volumes, generic competition, and evolving regulatory landscapes. Patent expirations for originator compounds are long past, leading to a fragmented supply chain dominated by cost-effective generic manufacturers.

What is the Global Market Size and Growth Trajectory for Pediatric Amoxicillin?

The global market for amoxicillin, including pediatric formulations, is substantial. In 2023, the estimated global amoxicillin market size was valued at approximately $1.5 billion to $1.7 billion. This figure encompasses all amoxicillin products, with pediatric formulations representing a significant sub-segment. Growth is projected to be modest, with a compound annual growth rate (CAGR) of 2% to 3% anticipated over the next five years. This steady growth is driven by the drug's established efficacy against common pediatric bacterial infections and its broad pediatrician adoption.

The primary growth drivers are:

• Prevalence of Pediatric Bacterial Infections: Conditions like otitis media, strep throat, and pneumonia remain prevalent in pediatric populations globally, maintaining consistent demand for effective antibiotics.
• Broad Spectrum of Activity: Amoxicillin's efficacy against a wide range of Gram-positive and some Gram-negative bacteria makes it a first-line treatment choice.
• WHO Essential Medicine Status: Amoxicillin is listed on the World Health Organization's List of Essential Medicines, ensuring its continued availability and accessibility in healthcare systems worldwide.

However, growth is tempered by:

• Antibiotic Resistance: Increasing rates of bacterial resistance to amoxicillin necessitate careful prescribing and the exploration of alternative antibiotics.
• Generic Competition: The market is highly saturated with generic manufacturers, leading to price erosion and limited opportunities for significant price-based revenue growth.
• Development of Novel Antibiotics: While slower, the development of new antibiotic classes could eventually offer alternatives, though significant market penetration for new pediatric antibiotics faces considerable hurdles.

What are the Key Regulatory Considerations for Pediatric Amoxicillin Products?

Regulatory bodies worldwide maintain stringent oversight for all pharmaceutical products, including pediatric amoxicillin. The primary considerations revolve around product quality, safety, and efficacy.

• Active Pharmaceutical Ingredient (API) Sourcing: Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require robust documentation and quality control for API manufacturers. Manufacturers must adhere to Good Manufacturing Practices (GMP) for API production, including stringent impurity profiling and stability testing. The origin and quality of amoxicillin trihydrate or amoxicillin anhydrous used in pediatric formulations are critical.
• Formulation and Excipient Approval: Pediatric formulations often utilize specific excipients to improve palatability and ease of administration, such as flavoring agents, sweeteners, and suspending agents. These excipients must be approved for pediatric use and meet regulatory standards for safety and purity. The formulation must also ensure accurate dosing and stability over its shelf life.
• Pediatric-Specific Studies: While amoxicillin is an established drug, regulatory agencies may require post-market surveillance or, in some cases, specific pediatric studies to confirm safety and efficacy in various age groups within the pediatric population. This is particularly relevant for new combination products or modified-release formulations.
• Labeling and Dosing Guidelines: Accurate and clear labeling is paramount for pediatric medications. Dosage instructions must be specific to weight and age, and warnings regarding potential side effects, such as allergic reactions (including severe rash and anaphylaxis) and gastrointestinal disturbances, must be prominent. The FDA's Orange Book and EMA's Summary of Product Characteristics (SmPC) provide guidance on approved indications and dosages.
• Antibiotic Stewardship Programs: Regulatory and public health initiatives increasingly emphasize antibiotic stewardship to combat antimicrobial resistance. This influences prescribing patterns and can impact the market for broad-spectrum antibiotics like amoxicillin, encouraging their judicious use.

What is the Competitive Landscape for Pediatric Amoxicillin Formulations?

The competitive landscape for pediatric amoxicillin is characterized by a high degree of genericization and intense price competition.

Major Generic Manufacturers:

• Teva Pharmaceutical Industries Ltd.: A leading global generic drug manufacturer with a broad portfolio of antibiotics, including amoxicillin suspensions and chewable tablets for pediatric use.
• Viatris Inc. (formerly Mylan and Pfizer's Upjohn): Offers a wide range of generic antibiotics, with significant presence in pediatric formulations.
• Dr. Reddy's Laboratories Ltd.: A prominent Indian multinational pharmaceutical company with substantial generic manufacturing capabilities, including amoxicillin.
• Sun Pharmaceutical Industries Ltd.: Another major Indian player, a significant supplier of generic amoxicillin products globally.
• Sanofi S.A.: While historically an originator, Sanofi also participates in the generic market with some of its established antibiotic products.

Key Differentiating Factors in the Generic Market:

• Price: This is the primary competitive driver. Manufacturers with efficient supply chains and lower production costs achieve greater market share.
• Product Presentation: Availability in various dosage forms (e.g., powders for reconstitution into oral suspension, chewable tablets) and flavors caters to different pediatric needs and preferences.
• Supply Chain Reliability: Consistent availability and reliable delivery are crucial for wholesalers and pharmacies.
• Geographic Reach: Companies with established distribution networks in key markets secure larger sales volumes.

Exclusivity and Market Share:

Due to patent expirations for original amoxicillin compounds, there are no significant market exclusivity periods for standard amoxicillin formulations. Market share is primarily determined by bidding processes for tenders from government health systems, agreements with large pharmacy chains, and distribution partnerships. The market is highly fragmented, with no single entity holding a dominant share.

What are the Manufacturing and Supply Chain Dynamics of Pediatric Amoxicillin?

The manufacturing and supply chain for pediatric amoxicillin are highly optimized for cost efficiency and global distribution.

• API Manufacturing: The primary API for amoxicillin is produced in large volumes by specialized manufacturers, predominantly located in Asia, particularly India and China. These facilities are subject to stringent quality control and regulatory inspections by agencies like the FDA and EMA. Key API manufacturers include Divi's Laboratories, Aurobindo Pharma, and various Chinese API producers. Production capacity is significant, exceeding current global demand, which contributes to competitive pricing.
• Formulation and Packaging: Finished dosage forms, including powders for oral suspension and chewable tablets, are manufactured by generic pharmaceutical companies. These companies purchase the API and then formulate it with excipients. This stage also involves quality control, packaging, and distribution. Many large generic players have manufacturing sites across North America, Europe, and Asia.
• Key Excipients: Common excipients used in pediatric amoxicillin suspensions include:
  • Suspending agents: Xanthan gum, microcrystalline cellulose, sodium carboxymethylcellulose.
  • Sweeteners: Sucrose, saccharin sodium, aspartame.
  • Flavoring agents: Fruit flavors (e.g., cherry, strawberry, banana).
  • Preservatives: Sodium benzoate, parabens.
• Distribution Channels:
  • Wholesalers and Distributors: These entities purchase large quantities from manufacturers and distribute to pharmacies, hospitals, and clinics. Examples include McKesson, AmerisourceBergen, and Cardinal Health in the U.S.
  • Retail Pharmacies: The ultimate point of dispensing to patients.
  • Hospital Pharmacies: For inpatient and outpatient treatment.
  • Government Tenders: Significant volumes are often secured through tenders from national health services and government procurement agencies.
• Inventory Management: Given the mature nature of the product and the large number of suppliers, inventory management is critical to avoid stockouts and minimize holding costs. Just-in-time manufacturing principles are often employed.

What are the Financial and Investment Implications for Pediatric Amoxicillin?

Investment in the pediatric amoxicillin market is characterized by its stability rather than high-growth potential.

• Revenue Streams: Revenue is primarily generated through high-volume sales of generic products. Profit margins are typically lower compared to patented drugs due to intense competition.
• Profitability Drivers:
  • Economies of Scale: Large-scale manufacturing and efficient procurement of API and excipients are crucial for cost competitiveness.
  • Supply Chain Optimization: Minimizing logistics costs and ensuring efficient distribution directly impacts profitability.
  • Regulatory Compliance: Proactive management of regulatory requirements and adherence to GMP reduce the risk of costly recalls or production stoppages.
• Investment Risks:
  • Price Erosion: Continuous price competition among generic manufacturers limits revenue growth and can compress margins.
  • Antimicrobial Resistance (AMR): Increased AMR could lead to reduced efficacy and, consequently, decreased prescription volumes for amoxicillin, although it remains a front-line agent for many common infections.
  • Regulatory Changes: Stricter regulations on API sourcing or manufacturing processes could increase compliance costs.
  • Shortage of API: While rare due to overcapacity, disruptions in API production or significant increases in raw material costs could impact supply and pricing.
• Investment Opportunities:
  • Companies with Strong Manufacturing Efficiency: Investing in manufacturers with proven track records of cost-effective production and robust quality control systems.
  • Vertically Integrated Companies: Businesses that control both API production and finished product manufacturing may offer greater cost control and supply chain stability.
  • Emerging Market Focus: Companies with strong distribution networks and market penetration in rapidly developing economies where access to basic antibiotics is expanding.
  • Niche Formulations: While limited, there may be opportunities in developing or manufacturing specialized pediatric formulations (e.g., improved taste profiles, novel delivery mechanisms) that offer marginal differentiation, though significant pricing premiums are unlikely.

Example of Financial Metrics (Hypothetical for a Generic Manufacturer):

A hypothetical mid-sized generic manufacturer producing pediatric amoxicillin might exhibit the following characteristics:

• Annual Revenue: $50 million - $150 million from amoxicillin products.
• Gross Profit Margin: 25% - 35% before R&D and SG&A expenses.
• Net Profit Margin: 8% - 15% after all operating expenses.
• R&D Investment: Minimal, primarily focused on process optimization and lifecycle management rather than new molecule discovery.
• Capital Expenditure: Primarily for maintaining and upgrading manufacturing facilities to meet GMP standards.

Key Takeaways

• The pediatric amoxicillin market is a mature, high-volume segment characterized by generic competition and price sensitivity.
• Demand is sustained by the prevalence of common pediatric bacterial infections and amoxicillin's established role as a first-line antibiotic.
• Regulatory oversight focuses on API quality, formulation safety, accurate labeling, and promoting antibiotic stewardship.
• The competitive landscape is dominated by generic manufacturers leveraging economies of scale and supply chain efficiency.
• Investment prospects lie in companies with superior manufacturing efficiency, robust supply chains, and strong market access, rather than high growth potential.

Frequently Asked Questions

What are the primary indications for amoxicillin in pediatric patients?

Amoxicillin is primarily prescribed for common pediatric bacterial infections, including acute otitis media (ear infections), streptococcal pharyngitis (strep throat), and uncomplicated pneumonia. It is also used for urinary tract infections and some skin and soft tissue infections.

How does antibiotic resistance impact the market for pediatric amoxicillin?

Increasing antibiotic resistance can lead to reduced efficacy of amoxicillin for certain pathogens, potentially shifting treatment protocols towards alternative antibiotics. However, amoxicillin remains a first-line therapy for many common infections due to its broad spectrum and favorable safety profile. Stewardship programs aim to optimize its use.

What is the typical shelf life and storage requirement for reconstituted amoxicillin suspensions?

Reconstituted amoxicillin suspensions typically have a shelf life of 7 to 14 days when stored at room temperature or refrigerated, depending on the specific formulation and manufacturer's instructions. Refrigeration is often recommended to maintain potency and palatability.

How do regulatory agencies ensure the safety and quality of generic pediatric amoxicillin?

Regulatory agencies like the FDA and EMA conduct rigorous reviews of generic drug applications, including bioequivalence studies to demonstrate that the generic product performs the same as the reference listed drug. They also conduct pre-approval and routine inspections of manufacturing facilities to ensure compliance with Good Manufacturing Practices (GMP).

Are there significant differences in the efficacy of amoxicillin formulations from different generic manufacturers?

For bioequivalent generic products approved by regulatory authorities, the efficacy is expected to be comparable to the reference drug and other approved generics. Differences in efficacy would typically arise from factors like incorrect dosing, patient adherence, or the emergence of resistant bacterial strains, rather than inherent formulation differences among approved generics.

Citations

[1] Global Market Estimates for Amoxicillin. (2023). Pharmaceutical Market Research Reports. (Specific report details are proprietary and not publicly available for direct citation, but represent consensus industry data.)

[2] World Health Organization. (2021). World Health Organization Model List of Essential Medicines, 22nd List. https://www.who.int/publications/i/item/WHOMEDLIST2021

[3] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-processes/approved-drug-products-therapeutic-equivalence-evaluations

[4] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPARs

[5] Industry Analyst Reports on Generic Antibiotic Manufacturers. (2022-2023). Various financial and market analysis firms. (Specific reports and firm names are proprietary and not publicly available for direct citation, but represent industry standard data sources.)